Share ownership Verici Dx plc

VRCI

GB00BM8HZD43

Medical Equipment, Supplies & Distribution

Market Closed - London S.E. Other stock markets 16:35:24 10/02/2026 GMT			5-day change	1st Jan Change
0.6900 ^GBX	-4.83%		-4.83%	-4.83%

02-05	EARNINGS AND TRADING: React sales increase; Arcontech profit declines	AN
02-05	Verici Dx's Tutivia Added as In-network Test Under BCBS Deal	MT

Share class: Verici Dx plc

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	242,541,467	200,838,769 ( 82.81 %)	0	82.81 %

Major shareholders: Verici Dx plc

Name	Equities	%	Valuation
Puma Investment Management Ltd. 10.46 %	158,300,000	10.46 %	2 M p
Canaccord Genuity Wealth Ltd. 9.991 %	151,212,458	9.991 %	2 M p
Unicorn Asset Management Ltd. 7.903 %	119,619,325	7.903 %	1 M p
UBS Asset Management (UK) Ltd. 7.817 %	118,314,708	7.817 %	1 M p
The Mount Sinai Hospital 1.288 %	19,501,330	1.288 %	194 038 p
Octopus Investments Ltd. 1.26 %	19,074,379	1.26 %	189 790 p
Hargreaves Lansdown Asset Management Ltd. 1.147 %	17,358,923	1.147 %	172 721 p
Maven Capital Partners UK LLP 0.8148 %	12,332,665	0.8148 %	122 710 p
Amati Global Partners LLP 0.8035 %	12,161,111	0.8035 %	121 003 p
Rathbones Investment Management Ltd. 0.6113 %	9,252,149	0.6113 %	92 059 p
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	40.76%
Other	2.09%
Renalytix Plc	0.57%
Individuals	0.3%
Unknown	56.28%

Based on 1000 largest holdings

Geographical origin of shareholders

United Kingdom	41.56%
United States	1.86%
Individuals	0.3%

Based on 1000 largest holdings

Verici Dx plc is an immuno-diagnostics development company. The Company develops a suite of tests forming a kidney transplant platform for personalized patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The principal activity is the development of prognostic and diagnostic tests for kidney transplant patients. The Company's kidney transplant assays use sequencing that defines a personalized risk-profile of each patient over the course of the transplant journey. The Company develops tests to understand how a patient is responding to organ transplants. Its products include Clarava, Tuteva and Protega. Clarava is a pre-transplant prognosis for the risk of early acute rejection (EAR). Tuteva is a post-transplant diagnostic focused upon acute cellular rejection (ACR), including subclinical rejection. Protega is a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. Its subsidiary is Verici Dx Inc.

Employees

Sector

Medical Equipment, Supplies & Distribution

Calendar

04-14 - Q4 2025 Earnings Release (Projected)

More about the company